An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy-Reference-Cited by-同舟云学术

An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

Published:2016-11-17 Issue:12 Volume:115 Page:1513-1519
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Qi Lishuang,Li Yang,Qin Yuan,Shi Gengen,Li Tianhao,Wang Jiasheng,Chen Libin,Gu Yunyan,Zhao Wenyuan,Guo Zheng

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016370.pdf

Reference36 articles.

1. Benjamini A, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57: 289–300.

2. Biliran H Jr, Wang Y, Banerjee S, Xu H, Heng H, Thakur A, Bollig A, Sarkar FH, Liao JD (2005) Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11 (16): 6075–6086.

3. Bland JM, Altman DG (2004) The logrank test. BMJ 328: 1073.

4. Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Ponten F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P (2013) Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19: 194–204.

5. Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD (2011) Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 103: 1859–1870.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer;Molecular Oncology;2024-01-25

2. ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis;Medicine;2023-09-08

3. A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma;Frontiers in Oncology;2022-09-15

4. Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma;Molecular Oncology;2022-07-22

5. Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer via Computed Tomography Derived Radiomic Features;Frontiers in Oncology;2022-06-22